Skip to main content
Midas Edge

HCW Biologics Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of changes in stockholders’ equity (deficit)

Condensed Statements of Changes in Stockholders’ Equity (Deficit)

For the Three and Six Months Ended June 30, 2025 and 2026

Stockholders’ Deficit
Common Stock · Additional Paid-In · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitDeficit
Balance, January 1, 2025185,589$19$93,785,946$(100,556,137)$(6,770,171)
Issuance of Common Stock upon exercise of stock options34—1,654—1,654
Issuance of Common Stock to Square Gate1,6031149,999—150,000
Issuance cost of Common Stock——(22,297)—(22,297)
Stock-based compensation——275,642—275,642
Net loss———(2,196,875)(2,196,875)
Balance, March 31, 2025187,226$20$94,190,944$(102,753,012)$(8,562,047)
Issuance of Common Stock32,37431,592,782—1,592,785
Issuance of pre-funded warrants——4,207,718—4,207,718
Issuance of Common Stock warrants——9,650,404—9,650,404
Exercise of pre-funded warrants85,523942—51
Issuance cost of Common Stock——(70,094)—(70,094)
Issuance cost of pre-funded warrants——(504,861)—(504,861)
Issuance cost of Common Stock warrants——(227,646)—(227,646)
Equity dividend to investor——(10,153,780)(10,153,780)
Issuance of Common Stock to extinguish restructured debt42,18141,774,108—1,774,112
Issuance of Common Stock warrants to extinguish restructured debt——544,249—544,249
Gain on conversion of debt with related parties, net——3,346,562—3,346,562
Stock-based compensation——278,307—278,307
Adjustment for reverse stock split10,4641(1)——
Net loss——-(1,927,730)(1,927,730)
Balance, June 30, 2025357,767$37$104,628,734$(104,680,742)$(51,972)
Stockholders’ Equity
Common Stock · Additional Paid-In · Accumulated · Total Stockholders’
SharesAmountCapitalDeficitEquity
Balance, January 1, 2026546,635$55$111,280,560$(108,515,846)$2,764,769
Common Stock issued in connection with abeyance shares (1)162,83416(16)--
Issuance of pre-funded warrants--1,499,753-1,499,753
Exercise of pre-funded warrants412,88241206-247
Reclassification of the modified warrant to liability--(1,595,778)-(1,595,778)
Issuance of Common Stock warrants--1,488,472-1,488,472
Equity dividend to investor--(1,488,472)-(1,488,472)
Issuance costs of Common Stock warrants--(181,198)-(181,198)
Issuance costs of pre-funded warrants--(207,858)-(207,858)
Stock-based compensation--10,019-10,019
Net income---3,472,4803,472,480
Balance, March 31, 20261,122,351$112$110,805,688$(105,043,366)$5,762,434
Issuance of Common Stock71,17471,101,772-1,101,779
Issuance of pre-funded warrants--6,243,229-6,243,229
Issuance of Common Stock warrants--6,809,392-6,809,392
Exercise of pre-funded warrants403,32240202-242
Reclassification of the modified warrant from liability--3,371,770-3,371,770
Equity dividend to investor--(10,154,642)-(10,154,642)
Issuance costs of Common Stock--(38,031)-(38,031)
Issuance costs of pre-funded warrants--(215,502)-(215,502)
Issuance costs of Common Stock warrants--(235,046)-(235,046)
Stock-based compensation--1,220-1,220
Adjustment for reverse stock split20,7952(2)--
Net loss---(5,219,231)(5,219,231)
Balance, June 30, 20261,617,642$161$117,690,050$(110,262,597)$7,427,614
(1)During the three months ended March 31, 2026, 162,834 shares previously issued on November 20, 2025, and held in abeyance, were issued. As of June 30, 2026, there were no shares held in abeyance.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.